← FDA DRUG APPROVALS

FDA NDA · NDA021621

ZYRTEC

cetirizine hydrochloride

Sponsor: KENVUE BRANDS

APPLICATION
NDA021621
TYPE
NDA
ORIGINAL APPROVAL
2004-03-16
LATEST ACTION
2026-03-24
ROUTE
ORAL
DOSAGE FORM
TABLET, CHEWABLE
MARKETING STATUS
Over-the-counter, Discontinued

Products

CHILDREN'S ZYRTEC ALLERGY · ReferenceOver-the-counter
CETIRIZINE HYDROCHLORIDE 2.5MG · TABLET, CHEWABLE · ORAL
CHILDREN'S ZYRTEC HIVES RELIEF · ReferenceDiscontinued
CETIRIZINE HYDROCHLORIDE 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, CHEWABLE · ORAL
CHILDREN'S ZYRTEC ALLERGY · ReferenceDiscontinued
CETIRIZINE HYDROCHLORIDE 5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, CHEWABLE · ORAL
CHILDREN'S ZYRTEC HIVES RELIEF · ReferenceDiscontinued
CETIRIZINE HYDROCHLORIDE 10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET, CHEWABLE · ORAL
CHILDREN'S ZYRTEC ALLERGY · ReferenceOver-the-counter
CETIRIZINE HYDROCHLORIDE 10MG · TABLET, CHEWABLE · ORAL

Approval history

2026-03-24Labeling · Supplement 18 · standardLabelAP
2024-08-15Labeling · Supplement 17 · standardLabelAP
2021-12-14Labeling · Supplement 12 · standardLetterAP
2020-11-30Manufacturing (CMC) · Supplement 10 · standardLabelAP
2007-11-16Efficacy · Supplement 5 · unknownLetterAP
2004-03-16Type 3 - New Dosage Form · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →